VAX-ID
Pre-clinical- Indications
- Drug delivery, Vaccination
Company intelligence / Profile preview
Idevax’s VAX-ID® is a CE-marked, patented device platform designed to enable accurate and user-independent intradermal drug delivery. The technology is intended to improve vaccine dose-sparing efficiency and patient comfort. As of mid 2025, the product is available for investigational/research use with commercial launch pending regulatory approvals.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Idevax.